Volume 15, Number 3—March 2009
Perspective
Meeting the Challenge of Influenza Pandemic Preparedness in Developing Countries
David S. Fedson
Table 2
Recent studies of patients with pneumonia treated with statins*
| Investigator (reference) | Study design and population | Principal outcome | Adjusted odds ratio (95% CI) or % reduction (p value) |
|---|---|---|---|
| van der Garde et al. (17) |
Case–control diabetes patients, 4,719/15,322 |
Pneumonia hospitalization |
0.50 (0.28-0.89) |
| Schlienger et al. (18) | Case–control, 1,227/4,734 | Pneumonia hospitalization | 0.63 (0.46–0.88) |
| 30-day pneumonia mortality rate |
0.47 (0.25–0.88) |
||
| Mortensen et al. (19) |
Retrospective cohort, 1,566/7,086 |
30-day pneumonia mortality rate |
0.54 (0.42–0.70) |
| Chalmers et al. (20) |
Prospective cohort, 257/750 |
30-day pneumonia mortality rate |
0.46 (0.25– 0.85) |
| Thomsen et al. (21) |
Retrospective cohort, 1,372/28,528 |
30-day pneumonia mortality rate |
0.69 (0.58–0.82) |
| Majumdar et al. (22) | Prospective cohort, 325/3,090 | Hospital mortality rate and ICU admission (adjusted for administrative data) | 0.88 (0.63–1.22) |
| Hospital mortality rate and ICU admission (adjusted for age, propensity score, clinical data, and functional status) |
1.10 (0.76–1.60) |
||
| Choi et al. (23) | Randomized controlled trial, ICU treatment; 33 with atorvastatin and 34 controls | ICU mortality rate | 45.4 (0.08) |
| Hospital mortality rate | 51.2 (0.026) |
